Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection

Current Opinion in HIV and AIDS

Volumn 9, Issue 3, 2014, Pages 210-216

  Derdeyn, Cynthia A ^a,b   Moore, Penny L ^c,d,e   Morris, Lynn ^c,d,e  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Centre for HIV and STIs National Institute for Communicable Diseases National Health Laboratory Services   (Ghana)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e Center for the AIDS Program of Research (CAPRISA)   (South Africa)

Author keywords

Affinity maturation; broadly neutralizing antibodies; HIV 1 envelope evolution; long CDRH3; unmutated common ancestor

Indexed keywords

BROADLY NEUTRALIZING ANTIBODY; HOST FACTOR; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIBODY RESPONSE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; EVOLUTION; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; NONHUMAN; ONTOGENY; PRIORITY JOURNAL; REVIEW; SOMATIC HYPERMUTATION; SOMATIC MUTATION; BIOSYNTHESIS; GENETICS; IMMUNOLOGY;

ANTIBODIES, NEUTRALIZING; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV INFECTIONS; HUMANS;

EID: 84898538468     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000057     Document Type: Review

References (57)

1. Klein F, Mouquet H, Dosenovic P, et al. Antibodies in HIV-1 vaccine development and therapy. Science 2013; 341:1199-1204.
2. Kwong PD, Mascola JR, Nabel GJ. Broadly neutralizing antibodies and the search for anHIV-1 vaccine: the end ofthe beginning. Nat Rev Immunol 2013; 13:693-701.
3. Mascola JR, Haynes BF. HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev 2013; 254:225-244.
4. Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol 2013; 31:705-742.
5. Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012; 37:412-425.
6. van Gils MJ, Sanders RW. Broadly neutralizing antibodies against HIV-1: templates for a vaccine. Virology 2013; 435:46-56.
7. Burton DR, Ahmed R, Barouch DH, et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 2012; 12:396-407.
8. Mikell I, Stamatatos L. Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject. PLoS One 2012; 7:e49610.
9. Wibmer CK, Bhiman JN, Gray ES, et al. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog 2013; 9:e1003738.
10. Bonsignori M, Montefiori DC, Wu X, et al. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J Virol 2012; 86:4688-4692.
11. Tomaras GD, Binley JM, Gray ES, et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol 2011; 85:11502-11519.
12. Moore PL, Ranchobe N, Lambson BE, et al. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog 2009; 5:e1000598.
13. Rong R, Li B, Lynch RM, et al. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog 2009; 5:e1000594.
14. Lynch RM, Rong R, Boliar S, et al. The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. J Virol 2011; 85:905-915.
15. Murphy MK, Yue L, Pan R, et al. Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth. PLoS Pathog 2013; 9:e1003173.
16. Gray ES, Moody MA, Wibmer CK, et al. Isolationofamonoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. J Virol 2011; 85:7719-7729.
17. Mikell I, Sather DN, Kalams SA, et al. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 2011; 7: e1001251.
18. Lynch RM, Tran L, Louder MK, et al. The development of CD4 binding site antibodies during HIV-1 infection. J Virol 2012; 86:7588-7595.
19. Liao HX, Lynch R, Zhou T, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013; 496:469-476.
20. Doria-Rose NA, Schramm CA, Gorman J, et al. Developmental pathway for potent V1V2-directed HIV-1 Neutralizing antibodies. Nature 2014. [Epub ahead of print]
21. Wu X, Zhou T, Zhu J, et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011; 333:1593-1602.
22. Sok D, Laserson U, Laserson J, et al. The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS Pathog 2013; 9:e1003754.
23. Klein F, Diskin R, Scheid JF, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 2013; 153:126-138.
24. Gray ES, Madiga MC, Hermanus T, et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 2011; 85:4828-4840.
25. Euler Z, van den Kerkhof TL, van Gils MJ, et al. Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity. J Virol 2012; 86:2045-2055.
26. Hraber P, Seaman MS, Bailer RT, et al. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 2014; 28:163-169.
27. Moore PL, Gray ES, Wibmer CK, et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 2012; 18:1688-1692.
28. Langedijk JP, Schuitemaker H. A sweet surprise for HIV broadly neutralizing antibodies. Nat Med 2012; 18:1616-1617.
29. van den Kerkhof TL, Feenstra KA, Euler Z, et al. HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. Retrovirology 2013; 10:102.
30. Klein F, Gaebler C, Mouquet H, et al. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med 2012; 209:1469-1479.
31. Piantadosi A, Panteleeff D, Blish CA, et al. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol 2009; 83:10269-10274.
32. Rademeyer C, Moore PL, Taylor N, et al. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology 2007; 368:172-181.
33. Powell RL, Kinge T, Nyambi PN. Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus. J Virol 2010; 84:9415-9426.
34. Cortez V, Odem-Davis K, McClelland RS, et al. HIV-1 superinfection inwomen broadens and strengthens the neutralizing antibody response. PLoS Pathog 2012; 8:e1002611.
35. Moore PL, Gray ES, Sheward D, et al. Potent and broad neutralization ofHIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol 2011; 85:3128-3141.
36. Moore PL, Sheward D, Nonyane M, et al. Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. J Virol 2013; 87:4882-4894.
37. Euler Z, van Gils MJ, Boeser-Nunnink BD, et al. Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individuals. PloS One 2013; 8:e54684.
38. Ferreira CB, Merino-Mansilla A, Llano A, et al. Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations. J Virol 2013; 87:12227-12236.
39. Boliar S, Murphy MK, Tran TC, et al. B-lymphocyte dysfunction in chronic HIV-1 infection does not prevent cross-clade neutralization breadth. J Virol 2012; 86:8031-8040.
40. Jelicic K, Cimbro R, Nawaz F, et al. The HIV-1 envelope protein gp120 impairs B cell proliferation by inducing TGF-beta1 production and FcRL4 expression. Nat Immunol 2013; 14:1256-1265.
41. Isik G, van Montfort T, Boot M, et al. Chimeric HIV-1 envelope glycoproteins with potent intrinsic granulocyte-macrophage colony-stimulating factor (GM-CSF) activity. PLoS One 2013; 8:e60126.
42. Isik G, Chung NP, van Montfort T, et al. An HIV-1 envelope glycoprotein trimer with an embedded IL-21 domain activates human B cells. PLoS One 2013; 8:e67309.
43. Melchers M, Bontjer I, Tong T, et al. Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. J Virol 2012; 86:2488-2500.
44. Excler JL, Tomaras GD, Russell ND. Novel directions in HIV-1 vaccines revealed from clinical trials. Curr Opin HIV AIDS 2013; 8:421-431.
45. Grimm SK, Ackerman ME. Vaccine design: emerging concepts and renewed optimism. Curr Opin Biotechnol 2013; 24:1078-1088.
46. Locci M, Havenar-Daughton C, Landais E, et al. Human circulating PD-(+)1CXCR3(-)CXCR5(+) memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 2013; 39:758-769.
47. Hoot S, McGuire AT, Cohen KW, et al. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog 2013; 9:e1003106.
48. McGuire AT, Glenn JA, Lippy A, Stamatatos L. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. J Virol 2014; 88:2645-2657.
49. McGuire AT, Hoot S, Dreyer AM, et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med 2013; 210:655-663.
50. Jardine J, Julien JP, Menis S, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013; 340:711-716.
51. Scharf L, West AP Jr, Gao H, et al. Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody. Proc Natl Acad Sci USA 2013; 110:6049-6054.
52. Sundling C, Li Y, Huynh N, et al. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. Sci Transl Med 2012; 4:142ra96.
53. Zolla-Pazner S, deCamp AC, Cardozo T, et al. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One 2013; 8:e53629.
54. Liao HX, Bonsignori M, Alam SM, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 2013; 38:176-186.
55. McLellan JS, Pancera M, Carrico C, et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011; 480:336-343.
56. Alam SM, Dennison SM, Aussedat B, et al. Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. Proc Natl Acad Sci USA 2013; 110:18214-18219.
57. Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477:466-470.